Pfizer Inc. (NYSE: PFE) announced that it will hold a conference call with investment analysts on Tuesday, November 3, 2026, at 10:00 am EST. The call is scheduled to provide an update on the company’s financial and operational results as detailed in its Third Quarter 2026 Performance Report, which will be issued that same morning.

Webcast access details

Investors and the general public are invited to view and listen to the live webcast. Access information and registration links are available on the Pfizer investor relations website. Participants are advised to register in advance of the scheduled time.

For those preferring audio-only participation, the conference call can be accessed via telephone using the following numbers:

• United States and Canada: 800-456-4352
• International: 785-424-1086
• Passcode: 11974

Replay availability

A transcript and a webcast replay of the conference call will be posted on the Pfizer investor relations website within 24 hours after the conclusion of the live event. These materials will remain accessible for a minimum of 90 days.

About Pfizer

Pfizer applies science and global resources to bring therapies that extend and significantly improve patients' lives. The company strives to set standards for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. For over 175 years, Pfizer has worked to make a difference for all who rely on its products.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced that the U.S. Food and Drug Administration has approved their supplemental Biologics License Application for the 2026-2027 COVID-19 vaccine formula targeting the XFG variant.

The approval covers use in adults ages 65 years and older, as well as individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. Shipping will begin immediately to ensure rapid access to this season’s vaccine.

Regulatory Basis and Variant Coverage

The FDA approval is based on cumulative clinical, non-clinical, and real-world data supporting the safety and effectiveness of COMIRNATY. Manufacturing and quality data showed that the XFG-adapted vaccine generated strong immune responses against currently circulating SARS-CoV-2 variants.

These variants include:

• XFG
• XFG.1.1
• NB.1.8.1
• PQ.17
• PQ.2.8.1

The selection of the XFG variant aligns with FDA guidance for the preferred composition of COVID-19 vaccines for use in the U.S. beginning in fall 2026.

Distribution and Historical Context

To date, more than five billion doses of COMIRNATY have been distributed globally. The companies stated the vaccine continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence.

BioNTech is the Marketing Authorization Holder for the Pfizer-BioNTech COVID-19 vaccine and its adapted vaccines in the United States, the EU, the United Kingdom, and other countries.

Safety Information

COMIRNATY is not recommended for individuals who had a severe allergic reaction after a previous dose of COMIRNATY or any Pfizer-BioNTech COVID-19 vaccine. Myocarditis and pericarditis have occurred in some people who received mRNA COVID-19 vaccines, most commonly in males 12 through 24 years of age.

Common side effects include injection site reactions, tiredness, headache, muscle pain, chills, joint pain, fever, nausea, and swollen lymph nodes.